Supplemental Table 1. Peptides selected for the quantification of the candidate biomarkers.

|  |  |  |  |
| --- | --- | --- | --- |
| **Accession No.** | **Protein Name** | **Protein ID** | **Peptides** |
| Q16610 | Extracellular matrix protein 1 | ECM1 | LLPAQLPAEK |
| NLPATDPLQR |
| P49747 | Cartilage oligomeric matrix protein | COMP | GDACDDDIDGDR |
| Q15113 | Procollagen C-endopeptidase 1 | PCOC1 | TGGLDLPSPPTGASLK |
| Q04756 | Hepatocyte growth factor activator | HGFA | VQLSPDLLATLPEPASPGR |
| LCNIEPDER |
| YEYLEGGDR |
| P07996 | Thrombospondin-1 | TSP1 | FVFGTTPEDILR |
| SITLFVQEDR |
| DCVGDVTENQICNK |
| P14780 | Matrix metalloproteinase-9 | MMP9 | LGLGADVAQVTGALR |
| QLAEEYLYR |
| AVIDDAFAR |
| P08253 | 72 kDa type IV collagenase | MMP2 | IDAVYEAPQEEK |
| TYIFAGDK |
| P02751 | Fibronectin | FINC | TYLGNALVCTCYGGSR |
| LLCQCLGFGSGHFR |
| SSPVVIDASTAIDAPSNLR |
| Q08380 | Galectin-3-binding protein | LG3BP | YSSDYFQAPSDYR |
| SQLVYQSR |
| IDITLSSVK |
| P23142 | Fibulin-1 | FBLN1 | DCSLPYATESK |
| IIEVEEEQEDPYLNDR |
| SQETGDLDVGGLQETDK |

Supplemental Table 2. Multivariate model of conversion to B2 phenotype using individual proteins by ELISA.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Quartile | | | |
| **Protein** | **1st** | **2nd** | **3rd** | **4th** |
| ECM1 | *ref* | 1.61 (0.67, 3.84) | 1.99 (0.81, 4.84) | 4.10 (1.82, 9.23) |
| FINC | *ref* | 0.81 (0.33, 1.97) | 1.81 (0.80, 4.09) | 2.06 (0.94, 4.54) |
| MMP9 | 1.91 (0.87, 4.18) | 1.37 (0.62, 3.05) | 0.71 (0.29, 1.73) | *ref* |
| COMP | 3.87 (1.28, 11.72) | 2.52 (0.53, 12.0) | 2.23 (0.68, 7.71) | *ref* |

Values are listed as hazard ratio with 95% confidence limits for conversion from B1 (inflammatory) to B2 (stricturing) phenotype. The best fit Cox regression model to the time of conversion to stricturing disease for each individual biomarker (by ELISA) included age, gender, disease location, change in height percentile over first 6 months and serum albumin at diagnosis.